Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 5/20 | 0.65 |
| ▸ | GCGR | P47871 | 18/20 | 0.63 |
| ▸ | GLP1R | P43220 | 2/20 | 0.59 |
| ▸ | GIPR | P48546 | 1/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267433 | 1.00 | GCG (0.65) | GCGGCGRGLP1RGIPRCHRM5 | |
| SCHEMBL2652700 | 0.96 | GCG (0.61) | GCGGCGRGLP1RGIPRCHRM5 | |
| SCHEMBL2275059 | 0.95 | GCG (0.63) | GCGGCGRGLP1RGIPRCHRM5 | |
| SCHEMBL2275062 | 0.95 | GCG (0.63) | GCGGCGRGLP1RGIPRCHRM5 | |
| SCHEMBL1765643 | 0.95 | GCG (0.70) | GCGGCGRGLP1RGIPRCHRM5 | |
| SCHEMBL2271801 | 0.95 | GCG (0.72) | GCGGCGRGLP1RGIPRCHRM5 | |
| SCHEMBL2271797 | 0.95 | GCG (0.72) | GCGGCGRGLP1RGIPRCHRM5 | |
| SCHEMBL2273256 | 0.93 | GCG (0.56) | GCGGCGRGLP1RGIPRCHRM5 | |
| SCHEMBL1765300 | 0.93 | GCG (0.69) | GCGGCGRGLP1RGIPRCHRM5 | |
| SCHEMBL2273407 | 0.93 | GCG (0.62) | GCGGCGRGLP1RGIPRCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| EP-1758859-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GCG 5/4885GCGR 2/4885GLP1R 1/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GCG 5/4885GCGR 2/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.